Collapsed as off-topic by two members at trust level 3 or above
Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.
Post #90 is the version of this I will quote in future. One addition.
My position on Step therapy requirements is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves surprise at the pharmacy.
I would put the burden of proof on the interesting explanation, not the dull one.
Second-hand on Step therapy requirements, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Everything in post #96 holds. The case it does not cover is the one I have.
Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
The step people skip is the one I have spelled out.
I keep a log for Step therapy requirements specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Two things can be true about Step therapy requirements at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
Tier placement and step therapy: some formularies place a medication on a higher tier or require you to fail cheaper alternatives before approving the one you want. Understanding the requirements before treatment starts matters.
I would rather say I do not know than round it up to an answer.
Where I part company with post #102, and it is a narrow parting.
Before the thread moves on from Step therapy requirements — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Adding the boring version of Step therapy requirements, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Reading back through, this was answered upthread and I missed it. My fault.
Building on post #104 rather than restating it.
Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.
Post #105 put the caveat in the right place and I want to underline it.
The question underneath Step therapy requirements is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
This follows post #108 rather than contradicting it.
I would put moderate confidence on the mainstream reading of Step therapy requirements and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Worth separating two things that post #108 runs together.
Out-of-pocket costs: if insurance is not covering it, asking about patient assistance programmes run by manufacturers can reduce costs. Eligibility requirements exist but many people qualify.
Post #109 describes the usual case. This is about the unusual one.
Two questions I would want answered before drawing anything from the Step therapy requirements data above: how were the cases selected, and what happened to the ones that dropped out.
Adding the measurement that post #109 says would settle it.
Careful with the language on Step therapy requirements. "Not detected" and "not present" are different findings and the first is a statement about the method.
Helpful, and short, which on this subject is harder than long.
Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves surprise at the pharmacy.
Picking up post #114: that is the part I would want checked first.
I would keep Step therapy requirements and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Coming back to post #114, because the follow-up matters more than the original answer.
Step therapy requirements looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
An honest declaration on Step therapy requirements: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Nothing to add on the substance. Thank you for taking the question at face value.